[Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation].
OBJECTIVE
To investigate the expression of IGF-IR and COX-2 in renal cell carcinoma(RCC). To explore the correlation among IGF-IR, COX-2 and PCNA expression.


METHODS
Immunohistochemical staining was performed to detect the expression of IGF-IR, COX-2 and PCNA in 64 cases of RCC.


RESULTS
The positive rates of IGF-IR expression and COX-2 expression were 60.9%(39/64) and 51.6%(33/64) in RCC respectively. The expressions of IGF-IR and COX-2 in RCC tissues were not related to the histological type of RCC (P>0.05), but they were related to and increased with the size and clinical stages of RCC (P<0.05). The expression of IGF-IR was related to pathological grades, but COX-2 was not. The expression of IGF-IR was positively related with the expression of COX-2 and PCNA respectively, but there was negative correlation between COX-2 and PCNA.


CONCLUSIONS
The experiment suggests that IGF-IR and COX-2 may produce a synergetic effect in oncogenesis and progression of RCC. Detection of these genes has positive effects on early diagnosis, malignancy determination, prognosis and treatment of RCC.
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. sunhang@fmmu.edu.cn
Hang
H
Sun
He
H
Wang
Wei-jun
WJ
Qin
Bo
B
Yang
Su-chun
SC
Wang
Bai-lu
BL
Jian
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000473:pathology*; D049109:Cell Proliferation; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018809:Proliferating Cell Nuclear Antigen / Q000096:biosynthesis; D017526:Receptor, IGF Type 1 / Q000096:biosynthesis*; D047368:Tumor Burden
D018809:Proliferating Cell Nuclear Antigen; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D017526:Receptor, IGF Type 1